WuXi XDC: Research feedback shows orders, capacity, and late-stage projects jointly supporting growth
AI summary card
WuXi XDC: Research feedback shows orders, capacity, and late-stage projects jointly supporting growth
Morgan Stanley maintains Overweight on WuXi XDC Cayman Inc. (2268.HK), with a target price of HK$83.00, and believes that a US$1.5bn backlog, GMP release at the Singapore DP site, and payload-linker demand will support revenue over the next 12-18 months.
- The backlog at the end of 2025 was US$1.5bn, mainly from D-stage projects (Phase 3 and Phase 2), and is expected to support revenue over the next 12-18 months.
- The company guides to a 2025-2030 revenue CAGR of 30-35%, 2026 revenue growth of about 35% in U.S. dollar terms, and gross margin of about 36%.
- The newly acquired Hefei base focuses on peptide and oligo synthesis; BioDlink has been consolidated since April, and its CDMO revenue is expected to double in 2026 and break even.
- Jiangyin's new payload-linker base has annual capacity of 3-5 tons, about 5x WuXi XDC's existing capacity in Wuxi; the company holds more than 24% of the overall market, close to second place behind Lonza.
- The Singapore DP site is expected to receive GMP release in the summer, and there is demand from more than 10 late-stage iCMC proposals; customers are expected to submit 4-5 BLAs in 2026.
Report interpretation
Overview
This report is Morgan Stanley's research feedback update on WuXi XDC Cayman Inc. (2268.HK), focusing on new capacity, M&A integration, ADC-related payload-linker demand, late-stage project progress, and valuation methodology. The report argues that the company's current growth is driven by R&D projects and D-stage projects, while commercial-contract contributions will provide additional upside beyond the base case.
Core views
The core view is constructive: first, the US$1.5bn backlog at the end of 2025 mainly comes from Phase 2/3 projects, improving revenue visibility over the next 12-18 months; second, the 2026 revenue growth and gross margin guidance are strong, with about 35% revenue growth in U.S. dollar terms and about 36% gross margin; third, newly added or integrated capacity in Jiangyin, Hefei, and Singapore is expected to expand payload-linker, peptides, oligos, and DP capabilities; fourth, the company has more than 24% share in the ADC-related market, and although Lonza has a stronger budget in mid- to late-stage and commercial contracts, WuXi XDC's current advantage is concentrated in early-stage projects.
Analysis framework
The report combines company research, order/backlog data, capacity release milestones, customer BLA submission expectations, peer competition positioning, and a DCF valuation framework to assess support for revenue over the next 12-18 months and upside in the share price.
Methodology notes
Discounted cash flow valuation
The target price is based on a DCF method, assuming a WACC of 10%, a perpetual growth rate of 5%, and HKD/RMB of 0.92, to reflect WuXi XDC's stage of development in a growth cycle and its medium- to long-term growth potential.
Internal forecasting framework
Unless otherwise stated, report metrics are based on the Morgan Stanley ModelWare framework; consensus data are provided by Refinitiv Estimates.
Overweight relative rating
Overweight means the expected risk-adjusted total return over the next 12-18 months is above the average of the analyst's industry coverage universe, and is not equivalent to a traditional Buy rating.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- WuXi XDC Cayman Inc. (2268.HK)Core coverage stock
- Strengths
- Adequate backlog, strong ADC-related payload-linker demand, new capacity expansion, and customer late-stage projects and BLA submission expectations provide revenue visibility.
- Weaknesses
- Current advantages are more concentrated in early-stage projects, and profitability improvement at new facilities still depends on utilization ramp-up.
- Comparison
- Compared with Lonza, which has a larger Advanced Synthesis budget and more exposure to mid- to late-stage and commercial contracts, WuXi XDC's overall market share exceeds 24%, making it the closest competitor in second place.
- Risks
- Slower biotech financing and pipeline progress, lower-than-expected late-stage and commercial-contract sales, and weaker-than-expected gross margin improvement at new facilities.
- WuXi Biologics Cayman Inc (2269.HK)Comparable company in the China healthcare/CDMO space
- Strengths
- Rated Overweight in Morgan Stanley's China healthcare coverage table, and the historical target-price series shows upward revisions in 2025-2026.
- Weaknesses
- The disclosed content mainly covers rating history and price-target history; the report does not extend to a fundamental analysis.
- Comparison
- It can serve as a peer reference for WuXi XDC in the biopharma outsourcing chain, but this report focuses on the research feedback on WuXi XDC's ADC/CDMO business.
- Risks
- The report provides only limited charts and disclosure, so it cannot be used to fully assess fundamental changes in 2269.HK.
Key data
- RatingOverweightIndustry view is Attractive.
- Target PriceHK$83.00This implies 47% upside versus the HK$56.65 closing price on 2026-05-12.
- 2026 Revenue Growth Guidanceabout 35%In U.S. dollar terms; the company also guides to a 2025-2030 revenue CAGR of 30-35%.
- 2026 Gross Margin Guidanceabout 36%Disclosed in the figure note.
- BacklogUS$1.5bnAs of end-2025, mainly Phase 3 and Phase 2 projects, supporting revenue over the next 12-18 months.
- Jiangyin Payload-linker Capacity3-5 tons/yearAbout 5x WuXi XDC's existing capacity in Wuxi.
- Market Share>24%The company is close to second place in the relevant market behind Lonza.
- Expected Customer BLA Submissions4-5Expected to be submitted in 2026, covering targets such as HER2, Claudin18.2, and Nectin-4.
- Market CapRmb59,773.1mnCurrent market capitalization disclosed in the table.
- 2026E RevenueRmb5,944mnTable forecast; subsequent-year forecasts are 2027E Rmb8,029mn, 2028E Rmb10,661mn, and 2029E Rmb14,067mn.
Impact & implications
If late-stage projects progress as planned, customer BLA submissions materialize, and new capacity in Singapore and Jiangyin ramps smoothly, WuXi XDC's revenue visibility, gross margin improvement, and valuation support will strengthen. Conversely, if biotech financing and pipeline progress slow, commercial-contract contributions fall short, or new-facility utilization ramps more slowly than expected, growth and margin improvement could come under pressure.
Risks
- Slower biotech financing and pipeline progress.
- Lower-than-expected late-stage and commercial-contract sales.
- Slower utilization ramp-up at new facilities such as the Singapore site, leading to less gross margin improvement than expected.
- A decline in global R&D outsourcing intensity.
- Further slowdown in biologics projects.
- Intellectual property protection or reputation risks.
- Morgan Stanley has investment-banking and other service relationships with covered companies, and investors should note potential conflicts of interest.
What to watch
- Progress on the Singapore DP site's summer GMP release and subsequent order conversion.
- Whether more than 10 late-stage iCMC proposals convert into actual contracts.
- Whether 4-5 customer BLA submissions in 2026 materialize on schedule, especially projects related to HER2, Claudin18.2, and Nectin-4.
- Commissioning and utilization ramp-up of Jiangyin's 3-5 tons/year payload-linker capacity.
- Whether BioDlink's CDMO revenue doubles in 2026 and breaks even after consolidation.
- Delivery on the 2025-2030 revenue CAGR guidance of 30-35% and the 2026 gross margin target of about 36%.